Table 2 PIPAC procedures
Characteristic / Data Item | Primary Tumor Entity | |
|---|---|---|
Breast Cancer | Endometrial Cancer | |
Number of patients (N = 44) | 28 | 16 |
Total number of procedures (N = 150) | 82 | 68 |
Completed procedures | 78 (95.1%) | 62 (91.2%) |
Completed PIPACs per patient | 3 (1–4), range 0–9 | 3.5 (1–6.75), range 0–10 |
7–10 procedures | 1 (3.6%) | 4 (25.0%) |
4–6 procedures | 9 (32.1%) | 4 (25.0%) |
2 or 3 procedures | 7 (25.0%) | 3 (18.8%) |
1 procedure | 10 (35.7%) | 2 (12.5%) |
0 procedures | 1 (3.6%) | 3 (18.8%) |
Primary non-access | 1 (1.3%) | 3 (4.8%) |
Secondary non-access | 1 (1.3%) | 2 (3.2%) |
RECIST | ||
Complete remission | 3 (10.7%) | – |
Partial remission | 9 (32.1%) | 4 (25.0%) |
Stable disease | 3 (10.7%) | 2 (12.5%) |
Disease progression | – | 1 (6.3%) |
Not determined / too few PIPACs | 13 (46.4%) | 9 (56.3%) |
Overall peri−/postoperative morbidity | 1 (0–2), range 0–4 | 1 (0–2), range 0–4 |
Total number of adverse events | 83 | 68 |
Procedures without complications | 34 (40.9%) | 28 (41.2%) |
CTCAE grade 1 | 21 (25.3%) | 21 (30.9%) |
CTCAE grade 2 | 19 (22.9%) | 16 (23.5%) |
CTCAE grade 3 | 7 (8.4%) | 3 (4.4%) |
CTCAE grade 4 | 2 (2.4%) | – |
Overall peri−/postoperative mortality | 0 | 0 |